NASDAQ:BRKR - Bruker Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $80.00
  • Forecasted Upside: 25.90 %
  • Number of Analysts: 4
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$63.54
▲ +0.78 (1.24%)

This chart shows the closing price for BRKR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bruker Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BRKR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BRKR

Analyst Price Target is $80.00
▲ +25.90% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Bruker in the last 3 months. The average price target is $80.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 25.90% upside from the last price of $63.54.

This chart shows the closing price for BRKR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 4 polled investment analysts is to hold stock in Bruker. This rating has held steady since April 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 1 sell ratings
1/9/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 1 sell ratings
4/9/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 1 sell ratings
7/8/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
10/6/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/4/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
6/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
7/3/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2022The Goldman Sachs GroupLower Price TargetSell$73.00 ➝ $60.00Medium
2/14/2022SVB LeerinkBoost Price TargetOutperform$84.00 ➝ $85.00Medium
11/2/2021Wells Fargo & CompanyBoost Price TargetEqual Weight$85.00 ➝ $90.00High
9/9/2021SVB LeerinkBoost Price TargetOutperform$90.00 ➝ $100.00Low
8/3/2021Wells Fargo & CompanyBoost Price TargetEqual Weight$70.00 ➝ $85.00High
8/3/2021CitigroupBoost Price TargetNeutral$75.00 ➝ $85.00High
6/18/2021SVB LeerinkBoost Price TargetOutperform$80.00 ➝ $85.00Medium
6/15/2021Cleveland ResearchUpgradeNeutral ➝ Buy$75.00High
5/6/2021BTIG ResearchBoost Price TargetBuy$73.00 ➝ $80.00Low
5/6/2021SVB LeerinkBoost Price TargetOutperform$70.00 ➝ $80.00Medium
2/17/2021CitigroupBoost Price Target$57.00 ➝ $65.00Low
2/17/2021Stifel NicolausBoost Price TargetIn-Line ➝ Hold$48.00 ➝ $65.00Low
2/5/2021Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$50.00 ➝ $55.00Medium
1/27/2021SVB LeerinkBoost Price TargetOutperform$50.00 ➝ $70.00High
12/17/2020BTIG ResearchBoost Price TargetBuy$50.00 ➝ $64.00Medium
12/16/2020Smith Barney CitigroupBoost Price Target$47.00 ➝ $57.00Low
12/2/2020The Goldman Sachs GroupInitiated CoverageSell$50.00Low
11/16/2020Wolfe ResearchUpgradeUnderperform ➝ Peer PerformMedium
8/4/2020CitigroupBoost Price TargetNeutral$38.00 ➝ $47.00Medium
8/4/2020Wells Fargo & CompanyBoost Price TargetOverweight$42.00 ➝ $52.00High
8/4/2020SVB LeerinkBoost Price TargetOutperform$45.00 ➝ $50.00High
7/20/2020Bank of AmericaBoost Price TargetBuy$43.00 ➝ $49.00Medium
5/13/2020Needham & Company LLCReiterated RatingHoldLow
5/7/2020CitigroupLower Price TargetNeutral$40.00 ➝ $38.00High
5/7/2020Wells Fargo & CompanyLower Price TargetOverweight$50.00 ➝ $42.00High
5/7/2020Needham & Company LLCReiterated RatingHoldHigh
5/1/2020Cleveland ResearchDowngradeBuy ➝ Neutral$37.50Low
4/28/2020UBS GroupLower Price TargetNeutral$53.00 ➝ $41.00Low
4/2/2020Stifel NicolausLower Price TargetHold$52.00 ➝ $35.00High
4/2/2020Wolfe ResearchDowngradeMarket Perform ➝ Underperform$27.00High
3/31/2020Needham & Company LLCDowngradeStrong-Buy ➝ HoldHigh
3/30/2020Wells Fargo & CompanyLower Price Target$60.00 ➝ $50.00Medium
3/30/2020SVB LeerinkLower Price TargetOutperform$58.00 ➝ $46.00High
3/26/2020BarclaysUpgradeEqual Weight ➝ Overweight$52.00 ➝ $48.00High
3/20/2020CitigroupLower Price TargetNeutral$52.00 ➝ $40.00High
2/19/2020Needham & Company LLCBoost Price TargetStrong-Buy$62.00 ➝ $63.00Medium
1/7/2020Wells Fargo & CompanyInitiated CoverageOverweight$60.00Medium
1/6/2020CitigroupInitiated CoverageBuy$52.00Low
1/3/2020Needham & Company LLCInitiated CoverageStrong-Buy$39.00High
12/23/2019Needham & Company LLCReiterated RatingBuy$62.00Low
11/14/2019Stifel NicolausInitiated CoverageHold$53.00High
9/27/2019Needham & Company LLCSet Price TargetBuy$58.00Low
9/26/2019Bank of AmericaUpgradeNeutral ➝ Buy$52.00Low
7/15/2019The Goldman Sachs GroupUpgradeSell ➝ Neutral$32.00 ➝ $48.00Low
6/24/2019Needham & Company LLCSet Price TargetStrong-Buy$46.00 ➝ $57.00Low
6/24/2019BarclaysReiterated RatingHold$44.00Low
6/21/2019Bank of AmericaReiterated RatingNeutral ➝ Neutral$44.00 ➝ $52.00Low
6/21/2019Jefferies Financial GroupBoost Price TargetBuy$45.00 ➝ $56.00Low
6/21/2019BTIG ResearchBoost Price TargetBuy$57.00Low
5/30/2019Wolfe ResearchInitiated CoveragePeer Perform ➝ Peer PerformLow
5/6/2019Needham & Company LLCReiterated RatingStrong-Buy ➝ Strong-Buy$39.00 ➝ $46.00Low
5/3/2019UBS GroupUpgradeSell ➝ Neutral$43.00High
5/3/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$40.00 ➝ $53.00High
4/12/2019Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$40.00 ➝ $50.00High
2/12/2019BTIG ResearchReiterated RatingBuy ➝ Buy$42.00 ➝ $44.00High
1/2/2019Needham & Company LLCInitiated CoverageStrong-Buy ➝ Strong-Buy$39.00High
10/9/2018UBS GroupInitiated CoverageSell ➝ Sell$30.00High
9/20/2018Morgan StanleyDowngradeEqual Weight ➝ Underweight$31.00 ➝ $32.00Low
8/3/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$29.00 ➝ $31.00High
7/13/2018Morgan StanleyLower Price TargetEqual Weight$31.00 ➝ $29.00Low
5/6/2018BTIG ResearchSet Price TargetBuy$42.00Low
5/4/2018Bank of AmericaLower Price TargetNeutral ➝ Neutral$37.00 ➝ $34.00N/A
4/11/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$32.00 ➝ $31.00Low
2/9/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$35.00 ➝ $32.00Low
2/9/2018SVB LeerinkBoost Price TargetMarket Perform ➝ Market Perform$32.00 ➝ $34.00High
1/5/2018BTIG ResearchInitiated CoverageBuy ➝ Buy$42.00High
1/3/2018Evercore ISIInitiated CoverageIn-Line$36.00Low
12/21/2017CowenReiterated RatingHold$35.00Low
12/14/2017Morgan StanleyReiterated RatingEqual Weight$35.00Low
11/3/2017CitigroupBoost Price TargetNeutral$29.00 ➝ $34.00N/A
11/3/2017CowenReiterated RatingHold$29.00N/A
11/3/2017Bank of AmericaUpgradeUnderperform ➝ Neutral$34.00N/A
11/3/2017JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$28.00N/A
9/26/2017The Goldman Sachs GroupReiterated RatingSell ➝ Sell$24.00Low
7/17/2017BarclaysReiterated RatingEqual Weight$26.00 ➝ $30.00Low
7/14/2017CowenReiterated RatingHold$29.00Low
7/12/2017Wells Fargo & CompanyDowngradeMarket Perform ➝ UnderperformMedium
(Data available from 7/3/2017 forward)

News Sentiment Rating

0.42 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 21 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
12/5/2021
  • 5 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/4/2022
  • 2 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/3/2022
  • 9 very positive mentions
  • 32 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/5/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/4/2022
  • 4 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
5/4/2022
  • 7 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/3/2022
  • 7 very positive mentions
  • 15 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
7/3/2022

Current Sentiment

  • 7 very positive mentions
  • 15 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Bruker logo
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Read More

Today's Range

Now: $63.54
Low: $61.98
High: $63.65

50 Day Range

MA: $60.94
Low: $56.38
High: $64.86

52 Week Range

Now: $63.54
Low: $55.80
High: $92.35

Volume

592,384 shs

Average Volume

783,052 shs

Market Capitalization

$9.48 billion

P/E Ratio

34.16

Dividend Yield

0.31%

Beta

1.18

Frequently Asked Questions

What sell-side analysts currently cover shares of Bruker?

The following Wall Street research analysts have issued reports on Bruker in the last twelve months: Citigroup Inc., StockNews.com, SVB Leerink LLC, The Goldman Sachs Group, Inc., and Wells Fargo & Company.
View the latest analyst ratings for BRKR.

What is the current price target for Bruker?

0 Wall Street analysts have set twelve-month price targets for Bruker in the last year. Their average twelve-month price target is $80.00, suggesting a possible upside of 25.9%.
View the latest price targets for BRKR.

What is the current consensus analyst rating for Bruker?

Bruker currently has 1 sell rating, 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BRKR, but not buy more shares or sell existing shares.
View the latest ratings for BRKR.

How do I contact Bruker's investor relations team?

Bruker's physical mailing address is 40 Manning Road, Billerica MA, 01821. The medical research company's listed phone number is (978) 663-3660 and its investor relations email address is [email protected] The official website for Bruker is www.bruker.com. Learn More about contacing Bruker investor relations.